10-K: ADMA Biologics Reports Record Net Income of $197.7 Million for 2024, Projects Continued Growth

ADMA Biologics achieves first-ever GAAP net income, reporting $197.7 million for 2024 and projecting significant revenue and earnings growth for 2025 and 2026.

Summary

• ADMA Biologics achieved its first GAAP net income of $197.7 million in 2024, a significant turnaround from previous years.
• The company generated positive cash flow from operations of $118.7 million in 2024.
• Revenue growth is attributed to increased acceptance and utilization of ASCENIV, along with contributions from BIVIGAM and Nabi-HB.
• ADMA projects revenues exceeding $490 million in 2025 and $605 million in 2026, with adjusted net income exceeding $175 million and $235 million, respectively.
• Adjusted EBITDA is projected to exceed $225 million in 2025 and $305 million in 2026.
• The company submitted a Prior Approval Supplement (PAS) to the FDA for a yield enhancement production process, potentially increasing production yields by approximately 20%.
• ADMA operates ten FDA-licensed plasma collection facilities and has supply agreements with Grifols and KEDPlasma for RSV plasma.
• The company anticipates filing a supplemental Biologics License Application (sBLA) in mid-2025 for the expansion of ASCENIV's label to include pediatric patients.

Sentiment

Score: 9

Explanation: The document presents a highly positive outlook with record net income, strong revenue growth, and promising future projections. The company's strategic initiatives and potential for increased production yields further contribute to the positive sentiment.

Positives

• Achieved first GAAP net income of $197.7 million in 2024.
• Generated positive cash flow from operations of $118.7 million in 2024.
• Projected revenue growth to over $490 million in 2025 and $605 million in 2026.
• Potential for increased production yields with FDA approval of the yield enhancement process.
• Expansion of ASCENIV's label to include pediatric patients is anticipated.

Negatives

• Reliance on third parties for filling, packaging, testing, and labeling of drug substance.
• Dependence on third parties for supply of raw material plasma.
• The plasma products industry is highly competitive.
• The market price of the common stock may be volatile.

Risks

• Inaccurate market opportunity estimates and forecasts of market and revenue growth.
• Potential regulatory actions from FDA inspections of facilities and suppliers.
• Business interruptions could adversely affect operations.
• Inability to obtain adequate quantities of FDA-approved source and high-titer plasma.
• Limitations on the ability to use net operating loss carryforwards (NOLs).
• Cyberattacks and other security breaches could compromise proprietary and confidential information.

Future Outlook

ADMA projects revenues exceeding $490 million in 2025 and $605 million in 2026, with adjusted net income exceeding $175 million and $235 million, respectively. Adjusted EBITDA is projected to exceed $225 million in 2025 and $305 million in 2026.

Management Comments

• The improved operating results are primarily the result of the substantial revenue growth and continued physician, patient and payer acceptance of ASCENIV.
• These elevated demand trends have sustained into 2025, and ADMA currently expects that this products rapid growth will continue throughout 2025 and beyond.

Industry Context

The U.S. market for immune and hyperimmune globulin products is estimated to be approximately $12 billion in 2023 and is expected to exceed $20 billion by 2030, indicating a growing demand for these therapies.

Comparison to Industry Standards

• The document mentions competitors such as CSL Behring, Grifols, Takeda, Octapharma and BPL/Kedrion.
• The document mentions an anti-FcRn inhibitor approved by the FDA in 2021 as a potential competitor to IVIG products for certain indications.

Related Party Transactions

• The Company leases an office building and equipment from Areth, LLC, a company controlled by Dr. Jerrold B. Grossman and Adam S. Grossman.
• The Company purchased certain specialized equipment and repair services used for the collection and processing of source plasma from GenesisBPS and its affiliates, owned by Dr. Grossman and Adam Grossman.
• The Company entered into an agreement with Bryant Fong whereby the Company agreed, in conjunction with Mr. Fongs resignation from the Board, to immediately vest all of Mr. Fongs 12,020 unvested RSUs.
• The Company entered into a consulting agreement with Brian Lenz, the Companys former Executive Vice President, Chief Financial Officer and General Manager, ADMA BioCenters, whereby Mr. Lenzs outstanding equity awards were modified in connection with his transition to a consulting role.

Stakeholder Impact

• Shareholders: Positive results and future projections are likely to increase shareholder value.
• Employees: Continued growth and profitability may lead to increased job security and potential for career advancement.
• Patients: Increased production capacity and potential label expansion could improve access to ADMA's therapies.
• Customers: Continued supply of high-quality plasma-derived products.
• Suppliers: Ongoing relationships and potential for increased demand.

Next Steps

• Advance biologic production yield enhancement initiative.
• Broadly implement innovative AI program, ADMAlytics.
• File sBLA in mid-2025 for ASCENIV label expansion.
• Continue animal studies for SG-001.

Key Dates